GSK-3α/β kinases and amyloid production in vivo

Arising from C. J. Phiel, C. A. Wilson, V. M.-Y. Lee & P. S. Klein 423, 435–439 (2003)10.1038/nature01640A major unresolved issue in Alzheimer’s disease is identifying the mechanisms that regulate proteolytic processing of amyloid precursor protein (APP)—glycogen synthase kinase-3 (GSK-3) isozymes are thought to be important in this regulation. Phiel et al. proposed that GSK-3α, but not GSK-3β, controls production of amyloid. We analysed the proteolytic processing of mouse and human APP in mouse brain in vivo in five different genetic and viral models. Our data do not yield evidence for either GSK-3α-mediated or GSK-3β-mediated control of APP processing in brain in vivo.

• Publication year

  2011

• Venue

  Nature

• Publication date

  2011-12-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature10615PMID 22158250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer's disease: old problem, new views from transgenic and viral models.

  2010cited by this paper
• Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model

  2010cited by this paper
• Light and Electron Microscopy Study of Glycogen Synthase Kinase-3β in the Mouse Brain

  2010cited by this paper
• Abnormalities in brain structure and behavior in GSK-3alpha mutant mice

  2009cited by this paper
• AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice

  2009cited by this paper
• A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

  2009cited by this paper
• Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

  2008cited by this paper
• Targeting glycogen synthase kinase-3 in Alzheimer's disease

  2006cited by this paper
• GSK-3 is essential in the pathogenesis of Alzheimer's disease

  2006cited by this paper
• Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.

  2006cited by this paper
• Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.

  2004cited by this paper
• GSK-3: tricks of the trade for a multi-tasking kinase

  2003cited by this paper
• GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

  2003cited by this paper
• GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

  2003cited by this paper
• Divergent roles of GSK3 and CDK5 in APP processing.

  2003cited by this paper
• FRAT1 peptide decreases Aβ production in swAPP751 cells

  2003cited by this paper
• Neuronal Deficiency of Presenilin 1 Inhibits Amyloid Plaque Formation and Corrects Hippocampal Long-Term Potentiation But Not a Cognitive Defect of Amyloid Precursor Protein [V717I] Transgenic Mice

  2002cited by this paper
• Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100.

  2002cited by this paper
• Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice.

  2000cited by this paper
• Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice*

  2000cited by this paper
• Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain*

  1999cited by this paper
• Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

  1998cited by this paper
• Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filaments

  1993cited by this paper
• Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments.

  1993cited by this paper

• Unveiling FOXO3's metabolic contribution to menopause and Alzheimer's disease.

  2025cites this paper
• Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer’s Disease (Type 3 Diabetes)

  2023cites this paper
• Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors

  2023cites this paper
• THE POTENT AND SELECTIVE HISTAMINE H3 RECEPTOR ANTAGONIST E169 ALLEVIATES COGNITIVE DEFICITS AND MITIGATES DISTURBED PI3K/AKT/GSK-3Β SIGNALING PATHWAY IN MK801 -INDUCED AMNESIA IN MICE

  2023cites this paper
• Unraveling the Effects of GSK-3β Isoform Modulation against Limbic Seizures and in the 6 Hz Electrical Kindling Model for Epileptogenesis.

  2022cites this paper
• Lithium and Therapeutic Targeting of GSK-3

  2021cites this paper
• The Amyloid-β Pathway in Alzheimer’s Disease

  2021cites this paper
• Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression

  2020cites this paper
• Machine Learning for Discovery of GSK3β Inhibitors

  2020cites this paper
• Lowered levels of nicotinic acetylcholine receptors and elevated apoptosis in the hippocampus of brains from patients with type 2 diabetes mellitus and db/db mice

  2020cites this paper
• GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer

  2020cites this paper
• Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease.

  2020cites this paper
• Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures

  2020cites this paper
• The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimer's Disease.

  2019cites this paper
• Emerging roles of GSK-3α in pathophysiology: Emphasis on cardio-metabolic disorders.

  2019cites this paper
• Three-dimensional modeling of human neurodegeneration: brain organoids coming of age

  2019cites this paper
• GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration

  2019cites this paper
• Correlation of Dickkopf-1 with Inflammation in Crohn Disease

  2019cites this paper
• The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

  2018cites this paper
• Rosmarinic Acid Derivatives’ Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer’s Disease

  2018cites this paper
• The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?

  2018cites this paper
• Mini-GAGR, an intranasally applied polysaccharide, activates the neuronal Nrf2-mediated antioxidant defense system

  2018cites this paper
• Investigating the Role of Glycogen Synthase Kinase-3 (GSK-3) in Pathological Progression of Alzheimer’s Disease

  2018cites this paper
• GSK3β activity alleviates epileptogenesis and limits GluA1 phosphorylation

  2018cites this paper
• Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update

  2017cites this paper
• Bidirectional interactions between diabetes and Alzheimer's disease.

  2017cites this paper
• Polo‐like kinase 2 phosphorylation of amyloid precursor protein regulates activity‐dependent amyloidogenic processing

  2017cites this paper
• Etude du métabolisme des pyramides du néocortex dans un modèle murin de la maladie d'Alzheimer - voies de signalisations impliquées dans la modulation de l'excitabilité des pyramides du néocortex par la noradrénaline

  2017cites this paper
• A Chemical-Genetic Approach Reveals the Distinct Roles of GSK3α and GSK3β in Regulating Embryonic Stem Cell Fate.

  2017cites this paper
• GSK3β Controls mTOR and Prosurvival Signaling in Neurons

  2017cites this paper
• Contribution of perforant path synaptic markers and GSK-3 to cognitive impairment and Alzheimer´s disease

  2016influential citation
• Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

  2016cites this paper
• Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid‐β (Aβ)42 peptides

  2016cites this paper
• The rise and fall of insulin signaling in Alzheimer’s disease

  2016cites this paper
• Ethyl Pyruvate Combats Human Leukemia Cells but Spares Normal Blood Cells

  2016cites this paper
• Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope

  2016cites this paper
• Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms.

  2016cites this paper
• GSK-3β and MMP-9 Cooperate in the Control of Dendritic Spine Morphology

  2016cites this paper
• Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.

  2016cites this paper
• The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease

  2015cites this paper
• Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice

  2015cites this paper
• Herpes Simplex Virus type-1 infection induces synaptic dysfunction in cultured cortical neurons via GSK-3 activation and intraneuronal amyloid-β protein accumulation

  2015cites this paper
• BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells

  2015cites this paper
• MicroRNA landscape in Alzheimer's disease.

  2015cites this paper
• Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β

  2014influential citation
• Wnt Signaling in Dementia

  2014cites this paper
• Wnt/β-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma

  2014cites this paper
• Mechanisms of Action of Phytochemicals from Medicinal Herbs in the Treatment of Alzheimerʼs Disease

  2014cites this paper
• Loss of neuronal GSK3β reduces dendritic spine stability and attenuates excitatory synaptic transmission via β-catenin

  2014cites this paper
• Neurotoxic Vulnerability Underlying Schizophrenia Spectrum Disorders

  2014cites this paper
• GSK3 in Alzheimer's Disease: Mind the Isoforms

  2014cites this paper
• A three-dimensional human neural cell culture model of Alzheimer’s disease

  2014cites this paper
• New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease

  2014cites this paper
• The role of ubiquitin-proteasome in the metabolism of amyloid precursor protein (APP): implications for novel therapeutic strategies for Alzheimer's disease.

  2014cites this paper
• Neurodegenerative Aspects in Vulnerability to Schizophrenia Spectrum Disorders

  2014cites this paper
• Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.

  2013cites this paper
• Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice.

  2013cites this paper
• Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes

  2013cites this paper
• Cyclin D2 knockout mice with depleted adult neurogenesis learn Barnes maze task.

  2013cites this paper
• Accelerated colorimetric immunosensing using surface-modified porous monoliths and gold nanoparticles

  2013cites this paper
• Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase

  2013cites this paper
• Tauopathy Differentially Affects Cell Adhesion Molecules in Mouse Brain: Early Down-Regulation of Nectin-3 in Stratum Lacunosum Moleculare

  2013cites this paper
• Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.

  2013cites this paper
• Design, Synthese und Optimierung von GSK-3-Inhibitoren und ihre Evaluation in Modellen der Alzheimer-Demenz

  2012cites this paper
• Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model

  2012cites this paper
• Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease

  2012cites this paper
• Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.

  2012cites this paper
• Central angiotensin II‐induced Alzheimer‐like tau phosphorylation in normal rat brains

  2012cites this paper
• Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis

  2012cites this paper
• Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice.

  2012cites this paper
• The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization.

  2012cites this paper
• GSK3 as a Sensor Determining Cell Fate in the Brain

  2012cites this paper
• Phiel et al. reply

  2011cites this paper
• Introduction Aims and Outline Alzheimer's Disease Uncovering Ad Pathogenesis Tau and Neurofibrillary Tangles Aβ and Senile Plaques

  year unknowncites this paper